Evidence map›Paper›PMID 40027080›Full record

ArticleExtracellular vesicle2023

Current challenges surrounding exosome treatments.

Eileen Tzng, Nathan Bayardo, Phillip C Yang

Abstract read
In one paragraph

Article in Extracellular vesicle, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Eileen TzngDivision of Cardiovascular Medicine and Cardiovascular Institute, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America.
Nathan BayardoDivision of Cardiovascular Medicine and Cardiovascular Institute, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America.
Phillip C YangDivision of Cardiovascular Medicine and Cardiovascular Institute, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States of America.

Funding

American Heart Association-American Stroke Association 19CSLOI34700047-YANG
6 · The paper itself

Abstract

Cardiovascular disease is the leading cause of death worldwide today and numerous studies are demonstrating that exosomes improve cardiac function after myocardial injury through various mechanisms. Exosome therapy has great potential as an effective precision medicine biologic by targeting the underlying disease process. However, this innovative approach may face some challenges, such as zeta potential, standardization of exosome collection, biopharmaceutical regulation, and more importantly, specific clinical application of exosome therapy. These issues will be addressed by broadly summarizing the biological plausibility; delivery, dosing, and pharmacokinetics; and reproducibility and manufacturing with a focus on microRNA as molecular cargo.

Indexed as

Cardiovascular diseaseExosomeTherapy

Identifiers

PMID40027080
PMCPMC11870656

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.